CSMG Technologies Announces 450 Successful Lung Surgical Procedures Completed.

CORPUS CHRISTI, Texas -- CSMG Technologies, Inc. (OTCBB:CTUM), a technology management company focused on commercializing human live tissue bonding devices, announced today that Kiev City Hospital #17, performed 450 successful lung surgeries using the Company's tissue welding technology in both open and thoracoscopic procedures.

The welding technology was used in surgical procedures that included: pneumolysis, pneumotomy, lymphodisseciton, lymph node sampling, wedge lung resections, sealing of peripheral part of the lung vessels. The welding technology is being routinely used for sealing lungs in cases of spontaneous pneumothorax and prolonged air leakage including bullous emphysema where the lung is repaired without removal of lung sections - no sutures, staples, glues or sealants were used.

Dr. Makarov holder of Thoracic Surgery and pulmonology chair at Kiev Medical Academy for Postgraduate Studies said, "There was not one case where there was lung air leakage or infection after the surgical procedure. The surgical procedures on lungs are done almost bloodlessly and the tissue welding method allows us to do surgeries much faster compared to the conventional techniques of suturing and stapling."

CSMG owns the technology and exclusive world rights to the medical device through Live Tissue Connect, Inc., a subsidiary corporation formed for the development and exploitation of the platform technology.

Donald S. Robbins, president and CEO of CSMG, said, "The main advantage of this breakthrough is a shortened surgery time and no foreign staples or sutures are left in the lung. The surgery leaves the healthy lung lobe portion functional in the body while removing the diseased lung lobe tissue."

The tissue welding/bonding technology for repair and reconnection of tissue and hollow organs is smokeless, with little heat migration in the tissue, results in no necrosis and is without the use of foreign matter or conventional wound-closing devices, such as of staples, sutures, glues or sealant. The procedures are almost bloodless. Unlike other tissue coagulation methods that tend to destroy tissue by charring, searing and necrosis, the CSMG-patented technology bonds and reconnects incised tissue using a patented low-heat delivery method aimed at restoring the normal functions of the live organs and tissue. The technology leaves little or no scar visible to the naked eye.

About CSMG Technologies' Tissue Welding/Bonding Technology

Surgeons at 10 Ukraine hospitals and clinics are using the tissue welding/bonding technology in clinical trials, have completed more than 6,000 human surgeries using almost 70 types of open and laparoscopic surgical procedures and demonstrated that the technology is universal in its ability to repair soft biological tissue. These surgeries included lung, neuro-surgery, nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, bladder, gynecology, fallopian tube, ovary and testicles, dura-matter, with little or no scarring, while restoring the normal function of the body organ or tissue.

The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine at Kiev, Ukraine, headed by Professor B.E. Paton. United States and Australia patents have been issued with other U.S. and foreign patents pending.

About CSMG Technologies, Inc.

CSMG Technologies is a technology management company that finances, owns, develops, licenses and markets innovative advanced technologies and business opportunities created in the Ukraine through a network of scientific institutes and private organizations. CSMG has three subsidiaries, Live Tissue Connect, Inc., CSMG Gastech, LLC and Anaerobic Farm Waste, Inc.

For further information on CSMG Technologies and it's various subsidiaries, please visit our website at www.ctum.com.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words ``may,'' ``would,'' ``will,'' ``expect,'' ``estimate,'' ``anticipate,'' ``believe,'' ``intend'' and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.